Urinary beta-glucuronidase in screening and followup of primary urinary tract malignancy.
The usefulness of urinary beta-glucuronidase in screening and followup of urinary tract malignancy was tested. The activity and concentration of urinary beta-glucuronidase were determined in 80 healthy subjects, 113 urology patients with no cancer, and 60 with transitional cell and 23 with renal cell carcinoma. Patients with cancer were followed for 3 to 33 weeks. The enzyme activity and concentration were significantly greater in the cancer group, including residual tumor or recurrence after therapy, than in the controls with excellent discrimination. Urinary beta-glucuronidase was indeed useful in screening and followup of urinary tract malignancy.